ACZONE DAPSONE GEL 7.5
Drug
Allergan Inc.
Total Payments
$31,953
Transactions
5
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $23,652 | 1 | 0 |
| 2017 | $8,302 | 4 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29,922 | 2 | 93.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000 | 2 | 6.3% |
| Education | $31.60 | 1 | 0.1% |
Payments by Type
Research
$29,922
2 transactions
General
$2,032
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An open-label study to investigate the efficacy and tolerability of Aczone gel, 7.5 in the treatment of acne vulgaris in men and women with Fitzpatrick skin types IV-VI | Allergan Inc. | $23,652 | 0 |
| SAFETY AND EFFICACY TRIAL OF ACZONE DAPSONE GEL, 7.5 IN 9 TO 11 YEAR-OLD PATIENTS WITH ACNE VULGARIS | Allergan Inc. | $6,270 | 0 |
Ad
Manufacturing Companies
- Allergan Inc. $31,953
Product Information
- Type Drug
- Total Payments $31,953
- Total Doctors 3
- Transactions 5
About ACZONE DAPSONE GEL 7.5
ACZONE DAPSONE GEL 7.5 is a drug associated with $31,953 in payments to 3 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Allergan Inc..
Payment data is available from 2017 to 2018. In 2018, $23,652 was paid across 1 transactions to 0 doctors.
The most common payment nature for ACZONE DAPSONE GEL 7.5 is "Unspecified" ($29,922, 93.6% of total).
ACZONE DAPSONE GEL 7.5 is associated with 2 research studies, including "An open-label study to investigate the efficacy and tolerability of Aczone gel, 7.5 in the treatment of acne vulgaris in men and women with Fitzpatrick skin types IV-VI" ($23,652).